Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Dosing Methods, Instructions for Use, and Safety Data Outcomes from a Phase 3 Study Evaluating the Efficacy and Safety of AZR-MD-001 0.5% for the Treatment of MGD and DED

David Wirta; Lyndon Jones; Christopher E. Starr; Preeya Gupta; Sumit Garg; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):5676.

ARVO Annual Meeting Abstract June 2025

Characteristics of Participants with Mild to Moderate MGD Utilizing AZR-MD-001 0.5% in a Randomized, Placebo-Controlled, Phase 3 Trial

Kelly Nichols; Francis Mah; David Wirta; Preeya Gupta; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):5675.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Efficacy in Resolving the Signs and Associated Symptoms of Contact Lens Discomfort in a Phase 2 Trial

Mark Hinds; Fiona Stapleton; Jacqueline Tan; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2971.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Opens Meibomian Glands, Improves Meibum and Tear Quality Resulting in Increased Wear Time and Desired Lens Use in Patients With CLD

Lyndon Jones; Julie Schallhorn; Fiona Stapleton; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2677.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Improved Corneal and Conjunctival Damage in Patients with CLD and MGD

Charles Bosworth; Mark Hinds; Eric G Kassel; Yair Alster

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2669.

ARVO Annual Meeting Abstract June 2024

Validity of the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and its comprehensiveness in assessing disease impact after the widespread adoption of digital media in patients with Contact Lens Discomfort (CLD) and concomitant Meibomian Gland Dysfunction (MGD)

Robin Chalmers; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5751.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Ophthalmic Ointment Opens Meibomian Glands, Improves Meibum Quality, and Tear Film Stability Over 3 Months of Dosing in Patients with Contact Lens Discomfort

Fiona Stapleton; Jacqueline Tan; Mark Hinds; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6584.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Improved Tear Film Stability and Ocular Symptoms in Patients with Meibomian Gland Dysfunction: 6-Month Results

Joshua C Teichman; Mark Hinds; Laura Elizabeth Downie; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6583.

ARVO Annual Meeting Abstract June 2024

Sign and Symptom Improvement Rates Among MGD Patients Following Treatment With AZRMD001 for 6 Months

Julie Marie Schallhorn; Lyndon Jones; Alison Ng; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6582.

ARVO Annual Meeting Abstract June 2024

Safety and Efficacy of Topical AZR-MD-001 for the Treatment of Meibomian Gland Dysfunction in a 6-Month Study

Jacqueline Tan; Fiona Stapleton; Laura Elizabeth Downie; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6578.

ARVO Annual Meeting Abstract June 2023

AZR-MD-001 efficacy in improving tear film stability and its impact on associated symptoms of meibomian gland dysfunction in a Phase 2 trial

Fiona Stapleton; Jacqueline Tan; Lyndon William Jones; Alison Ng; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4011.

ARVO Annual Meeting Abstract June 2023

AZR-MD-001 restores gland gunction and improves signs and ocular symptoms of mebomian gland dysfunction (MGD)

Preeya Gupta; Laura Elizabeth Downie; Mark Hinds; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5175.

ARVO Annual Meeting Abstract June 2023

AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis

Lisa Nijm; Jennifer P Craig; Mark Hinds; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5129.

ARVO Annual Meeting Abstract June 2023

Nonclinical assessment of repeated dosing of AZR-MD-001 to the lower eyelid (Selenium Sulphide, SeS 2 , sterile ophthalmic ointment): A novel therapy being developed for meibomian gland dysfunction

Limor Miara; Glenwood G Gum; Luba Litinetsky; Kathleen Krenzer; Linda Manza; Charles Bosworth; Yair Alster; Hila Epstin-Barash

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):172.

ARVO Annual Meeting Abstract June 2022

The effect of a novel selenium disulphide-containing topical treatment on ocular signs in individuals with meibomian gland dysfunction

Jacqueline Tan; Tianni Jia; Charles Bosworth; Nancy Briggs; Marc T Gleeson; Fiona Stapleton

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1535 – A0260.

ARVO Annual Meeting Abstract June 2021

A multicenter, double-masked, vehicle-controlled, randomized, parallel group clinical trial of AZR-MD-001 (AZR) in individuals with meibomian gland dysfunction

Laura Elizabeth Downie; Stephanie L Watson; Jacqueline Tan; Fiona Stapleton; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1334.

ARVO Annual Meeting Abstract June 2021

The effect of a novel selenium disulphide-containing treatment on ocular signs and symptoms in symptomatic contact lens wearers: An exploratory study

Fiona Stapleton; Jacqueline Tan; Tianni Jia; Venita DePuy; Marc Gleeson; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1259.

ARVO Annual Meeting Abstract June 2021

Randomized controlled trial evaluating novel keratolytic for MGD treatment

Jennifer P Craig; Fiona Stapleton; Jacqueline Tan; Susan Thackwray; Jagrut Lallu; Scott A Read; Karien Nel; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1252.

Glaucoma August 2001

Detecting Early Glaucoma by Assessment of Retinal Nerve Fiber Layer Thickness and Visual Function

PDF

Christopher Bowd; Linda M. Zangwill; Charles C. Berry; Eytan Z. Blumenthal; Cristiana Vasile; Cesar Sanchez-Galeana; Charles F. Bosworth; Pamela A. Sample; Robert N. Weinreb
TAGS: glaucoma, scanning laser polarimetry, retinal nerve fiber layer, shedler-westen assessment procedure–200, optic disk, roc curve, vision, eye
Invest. Ophthalmol. Vis. Sci.. 2001; 42(9):1993-2003.

Glaucoma June 2000

Visual Function–Specific Perimetry for Indirect Comparison of Different Ganglion Cell Populations in Glaucoma

PDF

Pamela A. Sample; Charles F. Bosworth; Eytan Z. Blumenthal; Christopher Girkin; Robert N. Weinreb
TAGS: eye, ganglia, glaucoma, perimetry, vision, shedler-westen assessment procedure–200, visual fields
Invest. Ophthalmol. Vis. Sci.. 2000; 41(7):1783-1790.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Dosing Methods, Instructions for Use, and Safety Data Outcomes from a Phase 3 Study Evaluating the Efficacy and Safety of AZR-MD-001 0.5% for the Treatment of MGD and DED

Characteristics of Participants with Mild to Moderate MGD Utilizing AZR-MD-001 0.5% in a Randomized, Placebo-Controlled, Phase 3 Trial

AZR-MD-001 Efficacy in Resolving the Signs and Associated Symptoms of Contact Lens Discomfort in a Phase 2 Trial

AZR-MD-001 Opens Meibomian Glands, Improves Meibum and Tear Quality Resulting in Increased Wear Time and Desired Lens Use in Patients With CLD

AZR-MD-001 Improved Corneal and Conjunctival Damage in Patients with CLD and MGD

Validity of the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and its comprehensiveness in assessing disease impact after the widespread adoption of digital media in patients with Contact Lens Discomfort (CLD) and concomitant Meibomian Gland Dysfunction (MGD)

AZR-MD-001 Ophthalmic Ointment Opens Meibomian Glands, Improves Meibum Quality, and Tear Film Stability Over 3 Months of Dosing in Patients with Contact Lens Discomfort

AZR-MD-001 Improved Tear Film Stability and Ocular Symptoms in Patients with Meibomian Gland Dysfunction: 6-Month Results

Sign and Symptom Improvement Rates Among MGD Patients Following Treatment With AZRMD001 for 6 Months

Safety and Efficacy of Topical AZR-MD-001 for the Treatment of Meibomian Gland Dysfunction in a 6-Month Study

AZR-MD-001 efficacy in improving tear film stability and its impact on associated symptoms of meibomian gland dysfunction in a Phase 2 trial

AZR-MD-001 restores gland gunction and improves signs and ocular symptoms of mebomian gland dysfunction (MGD)

AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis

Nonclinical assessment of repeated dosing of AZR-MD-001 to the lower eyelid (Selenium Sulphide, SeS 2 , sterile ophthalmic ointment): A novel therapy being developed for meibomian gland dysfunction

The effect of a novel selenium disulphide-containing topical treatment on ocular signs in individuals with meibomian gland dysfunction

A multicenter, double-masked, vehicle-controlled, randomized, parallel group clinical trial of AZR-MD-001 (AZR) in individuals with meibomian gland dysfunction

The effect of a novel selenium disulphide-containing treatment on ocular signs and symptoms in symptomatic contact lens wearers: An exploratory study

Randomized controlled trial evaluating novel keratolytic for MGD treatment

Detecting Early Glaucoma by Assessment of Retinal Nerve Fiber Layer Thickness and Visual Function

Visual Function–Specific Perimetry for Indirect Comparison of Different Ganglion Cell Populations in Glaucoma

To View More...

You must be signed into an individual account to use this feature.